Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Labcorp acquires assets of NMHS ambulatory outreach lab business

June 2025—Labcorp and North Mississippi Health Services announced that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and is now a referral laboratory for NMHS’ seven hospitals and clinic laboratories. In addition, Labcorp will open three patient service centers in Tupelo, West Point, and Amory by midyear to increase availability of laboratory services in North Mississippi.

FDA clears Liaison Plex Gram-negative blood culture assay

June 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-negative blood culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex. The assay is designed to identify 27 targets—19 Gram-negative bacteria and eight relevant resistance gene targets, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Acinetobacter species, Citrobacter species, Enterobacter species, and Proteus species. Results are available about two hours after a Gram stain.

Visby gets clearance, CLIA waiver for POC respiratory test

June 2025—Visby Medical announced it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its point-of-care Medical Respiratory Health test. The PCR test detects and differentiates between upper respiratory infections caused by influenza A and B and SARS-CoV-2 and provides results in less than 30 minutes.

Techcyte, Aiforia collaborate to advance AI-powered DP

June 2025—Techcyte and Aiforia announced a strategic partnership to accelerate the adoption of AI-driven workflows in anatomic pathology laboratories. The partnership brings together Techcyte’s Fusion digital pathology platform and Aiforia’s AI-powered diagnostic algorithms, beginning with the Aiforia breast cancer suite. The companies say the partnership will continue to drive innovation in digital pathology, cancer diagnostics, and more with an expanding portfolio of AI applications.

Qiagen gets clearance for second QIAstat-Dx mini GI panel

June 2025—Qiagen announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. The panel focuses on bacterial infections covering Campylobacter, Salmonella, Shiga-like toxin-producing E. coli, Shigella, and Yersinia enterocolitica. It is designed to complement the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, which covers Campylobacter, Salmonella, STEC, Shigella, and norovirus. The panel runs on the QIAstat-Dx system and delivers results in about one hour with less than one minute of hands-on time.

Sysmex adds XQ-320 to its line of three-part diff analyzers

June 2025—Sysmex America announced the expansion of its three-part differential automated hematology analyzer line with the XQ-320 for CBC testing. The XQ-320 has a throughput of up to 70 samples per hour, provides results in less than 60 seconds, and is the company’s first three-part differential analyzer that includes BeyondCare Quality Monitor. The analyzer features 17 parameters including an absolute neutrophil count, optional manual discrimination within histograms for challenging samples, robust flagging, and a low aspiration volume of 16 μL. It requires minimal weekly maintenance and offers a quick shutdown and automatic wake-up function.

Bio-Rad gets EU QMS certificate for 40 QC products

May 2025—Bio-Rad Laboratories has received the EU quality management systems certificate under IVDR regulation (EU) 2017/746, enabling the CE-IVDR marking of 40 Exact Diagnostics infectious disease molecular quality controls. The controls are formulated with whole organisms in relevant matrices to simulate patient specimens. This design aims to ensure that the controls undergo the same workflow and process challenges as patient specimens during routine testing.

Revvity gets FDA approval for automated TB test

May 2025—Revvity announced that the FDA has approved the Auto-Pure 2400 liquid handling platform with the T-Spot.TB test, for in vitro diagnostic use. The Auto-Pure 2400 tests up to 24 samples per run and completes day-one T-Spot.TB workflows in less than three and a half hours.

Thermo Fisher launches IVDR-compliant capillary electrophoresis system

May 2025—Thermo Fisher Scientific has introduced the Applied Biosystems SeqStudio Flex Dx genetic analyzer, an IVDR-compliant capillary electrophoresis system for Sanger sequencing and fragment analysis in targeted genomic testing. The system includes three operating modes—in vitro diagnostic use, investigational use only, and research use only—and is available in eight- and 24-capillary configurations. It features four-plate capacity, continuous plate loading with auto-spectral calibration capabilities, and urgent sample reprioritization.

Verichem electrolyte testing reference materials

May 2025—Verichem Laboratories offers liquid stable, multianalyte kits of clinical reference materials intended for the calibration verification of electrolyte assays. The materials are designed to be treated as patient samples for use with systems using flame photometer, direct and indirect ion-selective electrode, or standard enzymatic/colorimetric testing methods. The electrolyte standard kit contains the analytes chloride, ionized calcium, lithium, potassium, and sodium and features a 21-month stability claim; the ISE standard kit contains chloride, lithium, potassium, and sodium and offers an 18-month stability claim. Carbon dioxide assays are covered by the CO2 standard kit and the standalone, ultrahigh CO2 standard level F, which have a 15-month stability claim.

MARKETPLACE

TRENDING